Assessing Biomarker Analysis and the Use of EGFR- and ALK-Directed Therapy in Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer *(Video Program)*

FACULTY

Geoffrey R Oxnard, MD
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Lecia V Sequist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Center for Thoracic Cancers
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Lynette M Sholl, MD
Associate Pathologist
Brigham and Women's Hospital, Department of Pathology
Associate Director, Center for Advanced Molecular Diagnostics
Assistant Professor
Harvard Medical School
Boston, Massachusetts

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Foundation Medicine and Genentech BioOncology.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: January 2018

Select Publications

Geoffrey R Oxnard, MD

Oxnard GR et al. **Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer.** *J Clin Oncol* 2016;34(28):3375-82.

Lecia V Sequist, MD, MPH

Piotrowska Z, Sequist LV. **Treatment of *EGFR*-mutant lung cancers after progression in patients receiving first-line EGFR tyrosine kinase inhibitors.** *JAMA Onc* 2016;2(7):948-54.

Yang JC et al. **Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.** *Proc ASCO* 2016;**Abstract 9002**.

Yang JC et al. **Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.** *Lancet Oncol* 2015;16(7):830-8.

Lynette M Sholl, MD

Cutz JC et al. **Canadian anaplastic lymphoma kinase study: A model for multicenter standardization and optimization of ALK testing in lung cancer.** *J Thorac Oncol* 2014;9(9):1255-63.

Lindeman NI et al. **Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.** *J Thorac Oncol* 2013;8(7):823-59.

Marchetti A et al. **ALK protein analysis by IHC staining after recent regulatory changes: A comparison of two widely used approaches, revision of the literature, and a new testing algorithm.** *J Thorac Oncol* 2016;11(4):487-95.

Mino-Kenudson M et al. **A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.** *Clin Cancer Res* 2010;16(5):1561-71.

Reckamp KL et al. **A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma.** *J Thorac Oncol* 2016;11(10):1690-700.

Sholl LM et al. **Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.** *J Thorac Oncol* 2013;8(3):322-8.

Takeuchi K et al. **Prospective and clinical validation of ALK immunohistochemistry: Results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study).** *Ann Oncol* 2016;27(1):185-92.

Wynes MW et al. **An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators.** *J Thorac Oncol* 2014;9(5):631-8.